Luye Builds China Cancer Diagnosis Capability Via Vela Investment
This article was originally published in PharmAsia News
Executive Summary
As a Chinese healthcare player investing money into the oncology treatment market, Luye Group is seeking to stay ahead of the competition by adding disease screening and in vitro diagnostics to its arsenal, via a major investment into Vela Diagnostics of Singapore. As the window of opportunity closes in, the two are working quickly to bring products to the China market.